Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — H.C. Wainwright 28th Annual Global Investment Conference 2026
27 slides from Nykode Therapeutics Asa's conference presentation, Sep 16, 2026
Slide 1: H.C. Wainwright 28th Annual Global Investment Conference
H.C. Wainwright 28th Annual Global Investment Conference September 16, 2026 September 2026
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Investment highlights
Investment highlights Abi-suva - off-the-shelf - randomized ph2 in Individualized neoantigen therapy Antigen specific immune tolerance - novel HPV16+ 1L Head & Neck cancer (VB10.NEO) - validated as a class approach to address autoimmune diseases Clinical data across 3 indications in ~100 Positive pe
Slide 4: Strong pipeline of wholly owned assets with potential to drive growth
Strong pipeline of wholly owned assets with potential to drive growth Preclinical Phase 1 Phase 2 Phase 3 Next milestone Abi-suva (VB10.16) Completed Completed Ongoing Abili-T randomized Ph2 Off-the-shelf HPV16 vaccine interim analysis in 2027 Strong clinical data across HSIL, cervical 39% ORR vs. 1
Slide 5: Lead asset: abi-suva
Lead asset: abi-suva Off-the-shelf cancer vaccine Nykode Therapeutics | H.C. Wainwright 28th Annual Global Investment Conference - September 16, 2026 5
Slide 6: Abi-suva - a therapeutic cancer vaccine addressing HPV16+ cancers
Abi-suva - a therapeutic cancer vaccine addressing HPV16+ cancers HPV16 infection drives multiple cancer types The solution: abi-suva E6/E7 Persistent HPV16 infection is HPV16 viral oncogenes E6 & oncogenic and cause cancer Abi-suva E7 are strong cancer vaccine Off-the-shelf in several organs includ
Slide 7: The current focus of abi-suva is 1L r/m HNSCC with potential to expand
The current focus of abi-suva is 1L r/m HNSCC with the potential to expand to additional indications and lines of treatment Current focus of abi-suva Future potential for abi-suva 1L r/m HNSCC HPV16+ driven cancers Incidence of HPV16+ driven HNSCC cancers Incidence of HPV16+ driven cancers in EU in
Slide 8: Abi-suva shows strong and consistent clinical effect across several trials
Abi-suva shows strong and consistent clinical effect across several trials and HPV16 driven indications Consistent overall response rate (ORR) improvement compared to CPI monotherapy across indications Objective response rate (ORR) of abi-suva in combination with CPI compared to historical CPI monot
Slide 9: Immune responses strongly correlate with clinical outcomes across trials
Immune responses strongly correlate with clinical outcomes across trials C-02 2L+cervical cancer in combination with C-01 HSIL patients monotherapy atezolizumab 1500 1000 p=0.0113 500 • HPV16-specific T-cell 250 responses associated SFU/106 PBMC 200 with lesion size reduction 150 100 • Correlation o
Slide 10: Randomized Phase 2 Abili-T trial progressing well with first interim data expected in 2027
Randomized Phase 2 Abili-T trial progressing well with first interim data expected in 2027 Trial design Key inclusion criterion Treatment Endpoints ORR Abipapogene suvaplasmid + pembrolizumab PFS • HPV16+ r/m HNSCC DOR • PD-L1+ R RMDOR • Measurable disease (1:1) DCR • ECOG PS 0-1 OS • GRIm 0-1 TEAEs
Slide 11: HPV+ and HPV− head and neck cancer are two distinct cancer types
HPV+ and HPV− head and neck cancer are two distinct cancer types HPV negative HNSCC HPV positive HNSCC EGFR overexpression HPV viral oncogenes Plays a critical role in tumor growth, invasion and Drive tumor growth driven by HPV viral oncogenes metastasis EGFR is primarily overexpressed in HPV negati
Slide 12: VB10.NEO
VB10.NEO Individualized cancer vaccine Nykode Therapeutics | H.C. Wainwright 28th Annual Global Investment Conference - September 16, 2026 12
Slide 13: Individualized Neoantigen Therapy (INT) – a validated class of cancer vaccines
Individualized Neoantigen Therapy (INT) – a validated class of cancer vaccines 5. Treatment with 1. Biological Material INT Tumor biopsy & blood sample Clinically Validated Modality • Peer data (Moderna/MSD InterPATH-001) - first positive Phase 3 for an INT clinically validated the field Broad Appli
Slide 14: NeoSELECT: Nykode's proprietary clinically validated neoantigen selection
NeoSELECT : Nykode's proprietary clinically validated neoantigen selection across 13 tumor types • The proprietary AI-driven platform, NeoSELECTTM systematically prioritizes the most immunogenic neoantigens • Validated in clinical trials across multiple tumor types, including tumor types with low TM
Slide 15: Strong immune responses across 2 basket trials with heavily pre-treated patients
Strong immune responses across 2 basket trials with heavily pre-treated patients N-01 and N-02 both show vaccine induced immune response N-01 100 100% of patients in N-02 showed vaccine- N-02 85 85 88 induced immune responses, even in heavily pre-treated late-stage patients after few 58 vaccinations
Slide 16: Vaccine-specific T cells remain functional at least 1-year after last vaccination
Vaccine-specific T cells remain functional and immunogenic at least 1-year after last vaccination VB10.NEO induces a favorable and long-lasting T cell memory phenotype Nykode Therapeutics | H.C. Wainwright 28th Annual Global Investment Conference - September 16, 2026
Slide 17: Antigen-specific immunogenicity correlated with overall survival (OS)
Antigen-specific immunogenicity correlated with overall survival (OS) In patients with low baseline immunogenicity, more de-novo immune responses led to improved overall survival (N-01) Baseline low & de-novo high VB10.NEO antigen-specific immune Baseline low & de-novo low responses correlated with
Slide 18: Simpler pDNA production and manufacturing process compared to mRNA
Simpler pDNA production and simpler manufacturing process compared to mRNA positions VB10.NEO competitively in the INT field High potential for fast turn-around-time and simpler manufacturing process compared to mRNA pDNA Fermentation DNA Fill Product QA and Purification release mRNA Fermentation DN
Slide 19: Current optimized manufacturing process has turnaround time of less than 6 weeks
Our current optimized manufacturing process has a turnaround time (TAT) of less than 6 weeks Manufacturing Time (weeks) 18 14 • Current TAT of 5.9 competitive vs peers 9,3 • Clear path to further reduction by optimizing logistics 5,9 4 Target TAT with further consolidation manufacturing process Curr
Slide 20: Antigen-Specific Immune Tolerance
Antigen-Specific Immune Tolerance Nykode Therapeutics | H.C. Wainwright 28th Annual Global Investment Conference - September 16, 2026 20
Slide 21: Induction of antigen-specific immune tolerance by targeting epitopes to specific APCs
Induction of antigen-specific immune tolerance by targeting disease causing epitopes to specific APCs TARGETING SPECIFIC TOLERANCE INDUCTION Therapy delivered as rec. protein, or as pDNA through cell transfection APC-targeted B cells Effector Therapy B cell APCs Regulatory Regulatory T cell T cell D
Slide 22: Nykode's ASIT platform shows Best-In-Class potential
Nykode’s ASIT platform shows Best-In-Class potential Long durable reversion of Efficacy depends on the AI competencies for antigen selection and disease symptoms proprietary APC targeting optimal product design 30 µg 10 µg 3 µg Targeted 4 Non-targeted 4 5 PBS 4 EAE score (0-8) EAE score (0-8) EAE sc
Slide 23: Nykode's ASIT platform impacts all major arms of the immune system
Nykode’s ASIT platform impacts all major arms of the immune system Increase Reduce auto- Reduce regulatory antibodies Day 12 post EAE induction: effector T cells MOG-recall Splenocytes T cells anti-MOG (35-55) IgG Foxp3+ Treg cells ✱✱✱ Th1.17 cells IFN-γ Lag3 Day 7 % Foxp3+ of CD4+Thy1.2+ cells 30 ✱
Slide 24: Key takeaways from Nykode's ASIT platform
Key takeaways from Nykode’s ASIT platform Promising data show long-lasting efficacy across autoimmune disease models In house AI/ML expertise and multi-antigen design capabilities Wide potential across autoimmune diseases, allergy and organ transplant A high market potential with 1 in 10 being affec
Slide 25: Outlook
Outlook Nykode Therapeutics | H.C. Wainwright 28th Annual Global Investment Conference - September 16, 2026 25
Slide 26: Why invest in Nykode now
Why invest in Nykode now A whole category of cancer vaccines validated - Nykode operating in both INT and off-the-shelf cancer 1 vaccines 2 Lead asset abi-suva in randomized phase 2 building on encouraging data across 3 indications 3 Abi-suva’s Abili-T on track for first interim read-out in 2027 Nyk
Slide 27: Q&A
Q&A • Michael Engsig, CEO • Agnete Fredriksen, CSO and Business Development H.C. Wainwright 28th Annual Global Investment Conference - September 16, 2026 27
Nykode Therapeutics — H.C. Wainwright 28th Annual Global Investment Conference 2026 on 6ix